Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.
Clara MarquinaElla ZomerSandra Vargas-TorresSophia ZoungasRichard Ofori-AsensoDanny LiewZanfina AdemiPublished in: PharmacoEconomics (2021)
Based on current pricing and willingness-to-pay thresholds, most CEA studies considered ezetimibe, n-3 PUFAs and the polypill to be cost effective compared with standard care but not PCSK9 inhibitors for secondary prevention of CVD.